June 05, 2026
4 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Efdoralprin alfa improves endpoints in alpha-1 antitrypsin deficiency-related emphysema
ORLANDO — Compared with the current standard of care for patients with alpha-1 antitrypsin deficiency-related emphysema, investigational efdoralprin alfa showed better outcomes and similar safety, according to data presented here.This investigational therapy from Sanofi “is a recombinant human [alpha-1 antitrypsin-fragment crystallizable] fusion protein,” according to a company
1,195 words~5 min read
